These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35049682)

  • 1. The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors.
    Kolorz J; Demir S; Gottschlich A; Beirith I; Ilmer M; Lüthy D; Walz C; Dorostkar MM; Magg T; Hauck F; von Schweinitz D; Kobold S; Kappler R; Berger M
    Curr Oncol; 2021 Dec; 29(1):94-110. PubMed ID: 35049682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
    Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
    Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the Role of Neurokinin-1 Receptor Inhibition Using Aprepitant in the Apoptotic Cell Death through PI3K/Akt/NF-
    Ghahremanloo A; Javid H; Afshari AR; Hashemy SI
    Biomed Res Int; 2021; 2021():1383878. PubMed ID: 34395609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurokinin Receptor 1 (NK1R) Antagonist Aprepitant Enhances Hematoma Clearance by Regulating Microglial Polarization via PKC/p38MAPK/NFκB Pathway After Experimental Intracerebral Hemorrhage in Mice.
    Jin P; Deng S; Sherchan P; Cui Y; Huang L; Li G; Lian L; Xie S; Lenahan C; Travis ZD; Zhang JH; Gong Y; Tang J
    Neurotherapeutics; 2021 Jul; 18(3):1922-1938. PubMed ID: 34244927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant.
    Ebrahimi S; Mirzavi F; Aghaee-Bakhtiari SH; Hashemy SI
    Biochim Biophys Acta Mol Cell Res; 2022 May; 1869(5):119221. PubMed ID: 35134443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Blocking Neurokinin-1 Receptor by Aprepitant on the Inflammatory and Apoptosis Pathways in Human Ovarian Cancer Cells.
    AlAlikhan A; Ghahremanloo A; Javid H; Ebrahimi S; Hashemy SI
    Cell Biochem Biophys; 2022 Dec; 80(4):819-827. PubMed ID: 36197642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
    Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
    Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors.
    Halik PK; Lipiński PFJ; Matalińska J; Koźmiński P; Misicka A; Gniazdowska E
    Molecules; 2020 Aug; 25(16):. PubMed ID: 32824729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis.
    Alsaeed MA; Ebrahimi S; Alalikhan A; Hashemi SF; Hashemy SI
    Biomed Res Int; 2022; 2022():8082608. PubMed ID: 36177059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
    Coveñas R; Rodríguez FD; Robinson P; Muñoz M
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines.
    Muñoz M; Rosso M; Robles-Frias MJ; Salinas-Martín MV; Rosso R; González-Ortega A; Coveñas R
    Lab Invest; 2010 Aug; 90(8):1259-69. PubMed ID: 20458280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGFβ regulates NK1R-Tr to affect the proliferation and apoptosis of breast cancer cells.
    Wang L; Wang N; Zhang R; Dong D; Liu R; Zhang L; Ji W; Yu M; Zhang F; Niu R; Zhou Y
    Life Sci; 2020 Sep; 256():117674. PubMed ID: 32380077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
    Muñoz M; González-Ortega A; Coveñas R
    Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurokinin-1 receptor antagonist aprepitant regulates autophagy and apoptosis via ROS/JNK in intrahepatic cholangiocarcinoma.
    Yang Y; Cao X; Wang Y; Wu X; Zhou P; Miao L; Deng X
    Liver Int; 2024 Jul; 44(7):1651-1667. PubMed ID: 38554043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes.
    Liu X; Zhu Y; Zheng W; Qian T; Wang H; Hou X
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1628-1634. PubMed ID: 31010320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression.
    Mohammadi F; Javid H; Afshari AR; Mashkani B; Hashemy SI
    Mol Biol Rep; 2020 Jun; 47(6):4263-4272. PubMed ID: 32436041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The SP/NK1R system promotes the proliferation of breast cancer cells through NF-κB-mediated inflammatory responses.
    Jafarinezhad S; Assaran Darban R; Javid H; Hashemy SI
    Cell Biochem Biophys; 2023 Dec; 81(4):787-794. PubMed ID: 37740877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR.
    Zhang XW; Li L; Hu WQ; Hu MN; Tao Y; Hu H; Miao XK; Yang WL; Zhu Q; Mou LY
    Cell Death Dis; 2022 Jan; 13(1):41. PubMed ID: 35013118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
    Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
    Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.